Overview

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have advanced cancer and liver dysfunction
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Imatinib Mesylate